$71.10
4.20% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Vaxcyte Inc Stock price

$74.22
-16.69 18.36% 1M
-4.56 5.79% 6M
-7.64 9.33% YTD
-6.83 8.43% 1Y
+51.05 220.33% 3Y
+48.07 183.82% 5Y
+48.07 183.82% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-4.43 5.63%
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Key metrics

Market capitalization $9.56b
Enterprise Value $7.88b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.80
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-569.55m
Free Cash Flow (TTM) Free Cash Flow $-571.79m
Cash position $1.75b
EPS (TTM) EPS $-3.88
P/E forward negative
Short interest 12.32%
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vaxcyte Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Vaxcyte Inc forecast:

Buy
100%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 16 16
56% 56%
-
-16 -16
56% 56%
-
- Selling and Administrative Expenses 61 61
52% 52%
-
- Research and Development Expense 477 477
43% 43%
-
-554 -554
45% 45%
-
- Depreciation and Amortization 16 16
56% 56%
-
EBIT (Operating Income) EBIT -570 -570
45% 45%
-
Net Profit -464 -464
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
Seeking Alpha
2 days ago
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good aftern...
Neutral
GlobeNewsWire
3 days ago
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of Fir...
Neutral
GlobeNewsWire
16 days ago
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a ...
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 414
Founded 2013
Website www.vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today